Converging data from humans and laboratory animals suggest that altering bloodborne amylin could potentially reduce cerebrovascular amylin deposits and Aβ pathology in Alzheimer’s disease brains. Here, IAPP is linked to early-onset autosomal dominant Alzheimer disease.